Cargando…

A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study

BACKGROUND: Although B cell depletion with rituximab (RTX) is an effective treatment strategy in rheumatoid arthritis (RA), one third of patients do not achieve remission or low disease activity (LDA). Thus, identifying patients who will benefit from RTX is highly desirable. In the present study we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stradner, Martin H., Dejaco, Christian, Brickmann, Kerstin, Graninger, Winfried B., Brezinschek, Hans Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997751/ https://www.ncbi.nlm.nih.gov/pubmed/27558631 http://dx.doi.org/10.1186/s13075-016-1091-1

Ejemplares similares

B lymphocyte-typing for prediction of clinical response to rituximab
por: Brezinschek, Hans-Peter, et al.
Publicado: (2012)

The MHC2TA -168A>G gene polymorphism is not associated with rheumatoid arthritis in Austrian patients
por: Yazdani-Biuki, Babak, et al.
Publicado: (2006)

Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases Results of a lower dosage and shorter interval regimen
por: Moazedi-Fuerst, FC, et al.
Publicado: (2014)

Novel Senescent Regulatory T-Cell Subset with Impaired Suppressive Function in Rheumatoid Arthritis
por: Fessler, Johannes, et al.
Publicado: (2017)

Senescent T-Cells Promote Bone Loss in Rheumatoid Arthritis
por: Fessler, Johannes, et al.
Publicado: (2018)

Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders
por: Fasching, Patrizia, et al.
Publicado: (2017)

Rituximab for Refractory Rheumatoid Arthritis: A 24-Week Open-Label Prospective Study
por: Ho, Ling Yin, et al.
Publicado: (2007)

Rituximab for Rheumatoid Arthritis
por: Cohen, Marc D., et al.
Publicado: (2015)

The Value of Median Nerve Sonography as a Predictor for Short- and Long-Term Clinical Outcomes in Patients with Carpal Tunnel Syndrome: A Prospective Long-Term Follow-Up Study
por: Marschall, Alexander, et al.
Publicado: (2016)

B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients
por: Bruijnen, Stefan, et al.
Publicado: (2016)

Variants of genes implicated in type 1 interferon pathway and B-cell activation modulate the EULAR response to rituximab at 24 weeks in rheumatoid arthritis
por: Juge, Pierre-Antoine, et al.
Publicado: (2017)

Rituximab for the treatment of rheumatoid arthritis: an update
por: Mok, Chi Chiu
Publicado: (2013)

Rituximab and its potential for the treatment of rheumatoid arthritis
por: Bryant, Adam, et al.
Publicado: (2006)

Targeted therapies in rheumatoid arthritis: Focus on rituximab
por: Teng, YKO, et al.
Publicado: (2007)

Rituximab therapy in Greek patients with rheumatoid arthritis
por: Tsiakalos, Aristotelis P, et al.
Publicado: (2008)

Seronegative and seropositive rheumatoid arthritis treated with rituximab
por: Velloso Feijoo, Maria Luisa, et al.
Publicado: (2012)

Update on the use of rituximab for intractable rheumatoid arthritis
por: Looney, R John
Publicado: (2009)

Altered migratory capacity of polymorphonuclear leucocytes as an effect of TNF-alpha blockade in patients with rheumatoid arthritis
por: Mitterhammer, H, et al.
Publicado: (2001)

It’s more than dryness and fatigue: The patient perspective on health-related quality of life in Primary Sjögren’s Syndrome - A qualitative study
por: Lackner, Angelika, et al.
Publicado: (2017)

Repeated B-cell depletion with rituximab in rheumatoid arthritis
por: Edwards, J, et al.
Publicado: (2003)

Rituximab treatment in rheumatoid arthritis: how does it work?
por: Boumans, Maria JH, et al.
Publicado: (2009)

Treatment of Rheumatoid Arthritis with Biologic DMARDS (Rituximab and Etanercept)
por: Gashi, Afrim A., et al.
Publicado: (2014)

Long-term persistence with rituximab in patients with rheumatoid arthritis
por: Oldroyd, Alexander G S, et al.
Publicado: (2018)

Rituximab Therapy in Renal Amyloidosis Secondary to Rheumatoid Arthritis
por: Kilic, Levent, et al.
Publicado: (2018)

Tuberculosis Arthritis in the Wrist While Using Rituximab for Rheumatoid Arthritis Treatment
por: Ulusoy, Hasan, et al.
Publicado: (2020)

Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis
por: Iwamoto, Naoki, et al.
Publicado: (2017)

Ultrasound composite scores for the assessment of inflammatory and structural pathologies in Psoriatic Arthritis (PsASon-Score)
por: Ficjan, Anja, et al.
Publicado: (2014)

Efficacy and Safety of Rituximab in Biologic-Naive Patients with Rheumatoid Arthritis vs Anti-Tnf Therapy Failure
por: Gutierrez-Gonzalez, Luis Arturo, et al.
Publicado: (2013)

Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report
por: Lachowiez, Curtis, et al.
Publicado: (2017)

Sustained Remission After Combination Therapy with Rituximab and Etanercept in Two Patients with Rheumatoid Arthritis After TNF Failure: Case Report
por: Feuchtenberger, Martin, et al.
Publicado: (2009)

B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis
por: Tuscano, Joseph M, et al.
Publicado: (2009)

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2011)

Effect of concomitant statins on rituximab efficacy in patients with rheumatoid arthritis
por: Lehane, P B, et al.
Publicado: (2014)

Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis
por: Sweeney, Shannon R, et al.
Publicado: (2016)

(Ultra-)low dosing of rituximab in rheumatoid arthritis: chances and challenges
por: den Broeder, Alfons A, et al.
Publicado: (2021)

Enteroviral Meningoencephalitis as a Complication of Rituximab Therapy for Rheumatoid Arthritis
por: Cook, Samuel G, et al.
Publicado: (2021)

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
por: Fleischmann, R, et al.
Publicado: (2008)

Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis
por: Hainsworth, John D
Publicado: (2003)

Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
por: Mishra, Richa, et al.
Publicado: (2009)

Marked deterioration in rheumatoid arthritis associated bronchiectasis following treatment with Rituximab
por: Musameh, K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5f92fh9p8f5mqvmemnfqmejpi8